Digoxin therapy for heart failure: An update

American Family Physician

Volumn 74, Issue 4, 2006, Pages 613-618

  Morris, Spencer A ^a   Hatcher, H Floyd ^b   Reddy, Deepa K ^b  

^a Georgetown Hospital System   (United States)

^b Self Regional Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIGOXIN; PLACEBO;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; MORTALITY; REVIEW; SEX DIFFERENCE;

ALGORITHMS; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; SEX FACTORS; TREATMENT OUTCOME;

EID: 33747709456     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [Published correction appears in JAMA 1995;274:462]. JAMA 1995;273:1450-6.
3. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287:883-9.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [Published correction appears in N Engl J Med 2003;348:2271]. N Engl J Med 2003;348:1309-21.
6. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-44.
7. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1-7.
8. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, for the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial. J Am Coll Cardiol 1993;22:955-62.
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
10. Hunt SA. ACC/AHA 2005 guidelines for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [Published correction appears in J Am Coll Cardiol 2006;47:1503-5]. J Am Coll Cardiol 2005;46:el-82.
11. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and metaanalysis. Am J Med 1990;88:279-86.
12. Terra SG, Washam JB, Dunham GD, Gattis WA. Therapeutic range of digoxin's efficacy in heart failure: what is the evidence? Pharmacotherapy 1999;19:1123-6.
13. Beller GA, Smith TW, Abelmann WH, Haber E, Hood WB Jr. Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med 1971;284:989-97.
14. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
15. Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946-53.
16. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11.
17. Rich MW, McSherry F, Williford WO, Yusuf S, for the Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001;38:806-13.
18. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass.: Little, Brown & Co, 1994:253-6.
19. Klein L, O'Connor CM, Gattis WA, Zampino M, de Luca L, Vitarelli A, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations [Published correction appears in Am J Cardiol 2003;92:1378]. Am J Cardiol 2003;91(9A):18F-40F.
20. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003;138:917-24.
21. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 2002;105:1503-8.
22. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004;351:1097-105.
23. Sticherling C, Oral H, Horrocks J, Chough SP, Baker RL, Kim MH, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000;102:2503-8.
24. Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, et al., for the AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003;139:1009-17.